Profile data is unavailable for this security.
About the company
Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two pivotal Phase 3 clinical trials for use in combination with standard-of-care anti-VEGF-A monotherapies for the treatment of wet AMD and DME. The Company has also manufactured OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. Its development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).
- Revenue in USD (TTM)124.67k
- Net income in USD-220.24m
- Incorporated1984
- Employees--
- LocationOpthea LtdSuite 0403Level 4, 650 Chapel Street, South YarraMELBOURNE 3141AustraliaAUS
- Phone+61 39826-0399
- Fax+61 39824-0083
- Websitehttps://opthea.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allogene Therapeutics Inc | 43.00k | -283.43m | 644.06m | 232.00 | -- | 1.39 | -- | 14,978.22 | -1.53 | -1.53 | 0.0002 | 2.21 | 0.00007 | -- | -- | 185.34 | -43.56 | -28.46 | -46.04 | -30.21 | -- | -- | -659,137.20 | -1,123.44 | -- | -- | 0.00 | -- | -39.10 | -- | 3.86 | -- | -14.06 | -- |
| Tectonic Therapeutic Inc | 0.00 | -58.25m | 647.73m | 13.00 | -- | 3.89 | -- | -- | -18.52 | -18.52 | 0.00 | 11.29 | 0.00 | -- | -- | 0.00 | -35.55 | -45.22 | -40.16 | -49.14 | -- | -- | -- | -- | -- | -128.75 | 0.0066 | -- | -- | -- | 111.48 | -- | -66.27 | -- |
| AnaptysBio Inc | 57.17m | -165.66m | 648.44m | 117.00 | -- | 7.69 | -- | 11.34 | -6.07 | -6.07 | 2.09 | 2.77 | 0.1166 | -- | 7.39 | 488,649.60 | -33.78 | -18.08 | -36.91 | -18.96 | -- | -- | -289.75 | -269.21 | -- | -- | 0.00 | -- | 66.78 | 27.97 | -27.11 | -- | -5.36 | -- |
| Savara Inc | 0.00 | -75.29m | 653.46m | 37.00 | -- | 5.39 | -- | -- | -0.4317 | -0.4317 | 0.00 | 0.7361 | 0.00 | -- | -- | 0.00 | -58.02 | -36.86 | -62.14 | -39.54 | -- | -- | -- | -102,587.50 | -- | -- | 0.2066 | -- | -- | -- | -43.38 | -- | 15.91 | -- |
| Alumis Inc | 0.00 | -189.03m | 653.93m | 128.00 | -- | -- | -- | -- | -3.65 | -3.65 | 0.00 | 3.87 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -142.57 | 0.00 | -- | -- | -- | -38.47 | -- | -- | -- |
| Korro Bio Inc | 0.00 | -92.22m | 654.64m | 92.00 | -- | 3.30 | -- | -- | -30.51 | -30.51 | 0.00 | 21.34 | 0.00 | -- | -- | 0.00 | -56.06 | -31.55 | -59.82 | -36.48 | -- | -- | -- | -365.87 | -- | -167.13 | 0.00 | -- | -- | -- | 0.5001 | -- | 78.21 | -- |
| Astria Therapeutics Inc | 0.00 | -93.24m | 666.95m | 59.00 | -- | 2.58 | -- | -- | -2.30 | -2.30 | 0.00 | 6.32 | 0.00 | -- | -- | 0.00 | -32.43 | -64.48 | -33.78 | -68.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.62 | -- | -- | -- |
| Sana Biotechnology Inc | 0.00 | -244.90m | 668.51m | 328.00 | -- | 1.97 | -- | -- | -1.15 | -1.15 | 0.00 | 1.53 | 0.00 | -- | -- | 0.00 | -36.94 | -38.99 | -42.11 | -42.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.11 | -- | 112.71 | -- |
| Opthea Ltd (ADR) | 124.67k | -220.24m | 670.03m | -- | -- | -- | -- | 5,374.46 | -2.87 | -2.87 | 0.0016 | -0.5557 | 0.0009 | -- | 0.0136 | -- | -153.25 | -112.75 | -215.25 | -134.33 | 100.00 | -- | -176,660.10 | -113,428.10 | -- | -5.08 | 1.61 | -- | 15.00 | 1.86 | -54.53 | -- | 20.99 | -- |
| Y-mAbs Therapeutics Inc | 86.55m | -24.61m | 689.94m | 100.00 | -- | 7.24 | -- | 7.97 | -0.5618 | -0.5618 | 1.98 | 2.14 | 0.6262 | 1.42 | 4.19 | 865,460.00 | -17.81 | -44.23 | -23.58 | -50.45 | 88.74 | -- | -28.44 | -181.13 | 2.72 | -- | 0.00 | -- | 29.96 | -- | 77.58 | -- | -- | -- |
| Mineralys Therapeutics Inc | 0.00 | -119.67m | 698.16m | 28.00 | -- | 2.41 | -- | -- | -2.71 | -2.71 | 0.00 | 5.84 | 0.00 | -- | -- | 0.00 | -39.26 | -- | -41.62 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -141.28 | -- | -- | -- |
| Exscientia PLC (ADR) | 27.16m | -167.45m | 703.15m | 483.00 | -- | 1.81 | -- | 25.89 | -1.31 | -1.31 | 0.2137 | 3.01 | 0.042 | -- | 26.88 | 56,234.72 | -25.87 | -- | -29.52 | -- | -32.45 | -- | -616.50 | -- | -- | -- | 0.0674 | -- | -26.24 | -- | -22.94 | -- | -- | -- |
| Olema Pharmaceuticals Inc | 0.00 | -109.63m | 710.10m | 80.00 | -- | 3.13 | -- | -- | -2.06 | -2.06 | 0.00 | 3.97 | 0.00 | -- | -- | 0.00 | -50.73 | -30.06 | -56.10 | -31.40 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.76 | -- | -- | -- |
Data as of Nov 11 2024. Currency figures normalised to Opthea Ltd's reporting currency: US Dollar USD
3.75%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Regal Funds Management Pty Ltd.as of 30 Sep 2024 | 2.91m | 1.89% |
| Baker Bros. Advisors LPas of 30 Jun 2024 | 2.17m | 1.41% |
| Pengana Capital Ltd.as of 28 Jun 2024 | 270.42k | 0.18% |
| Teacher Retirement System of Texasas of 30 Jun 2024 | 269.40k | 0.18% |
| Millennium Management LLCas of 30 Jun 2024 | 71.17k | 0.05% |
| BMO Asset Management Corp.as of 30 Jun 2024 | 48.62k | 0.03% |
| Stratos Wealth Partners Ltd.as of 30 Sep 2024 | 29.60k | 0.02% |
| RBC Capital Markets LLC (Investment Management)as of 30 Jun 2024 | 6.00k | 0.00% |
| Victory Capital Management, Inc. (Investment Management)as of 30 Sep 2024 | 0.00 | 0.00% |
| Morgan Stanley & Co. LLCas of 30 Jun 2024 | 0.00 | 0.00% |
More ▼
Data from 28 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
